在亚临床甲状腺功能低下症和心力衰竭减少喷射分数的levothyroxine的影响:一个开放的标签随机试验
Wenyao Wang1, Xuan Zhang2, Jun Gao1
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.
Cell reports. Medicine
|March 27, 2024
概括
利沃甲状腺素 (L-T4) 改善了亚临床甲状腺功能低下症 (SCH) 和心力衰竭减少射出分数 (HFrEF) 的患者的运动能力和纽约心脏协会 (NYHA) 类. 这表明L-T4可能有利于SCH的HFrEF患者的联合治疗.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 临床试验 临床试验
背景情况:
- 亚临床甲状腺功能低下症 (SCH) 在心力衰竭患者中常见,心力衰竭的减少喷射率 (HFrEF).
- 在SCH的HFrEF患者中,勒沃西 (L-T4) 治疗的作用尚不清楚.
研究的目的:
- 研究L-T4在SCH和HFrEF患者中给予的临床益处.
- 评估L-T4对运动能力,功能类和甲状腺功能的影响.
主要方法:
- 一个随机的,多中心的,开放的标签试验 (NCT03096613) 涉及117名患者.
- 患者接受了L-T4加标准HFrEF治疗或单独接受标准HFrEF治疗.
- 评估结果包括6分钟步行测试 (6-MWT) 距离和纽约心脏协会 (NYHA) 在24周的分类.
主要成果:
- 与对照组相比,L-T4组在6MWT距离上表现出明显更大的改善 (平均差异:46.90 m,p < 0.001).
- 在L-T4组的NYHA分类 (p = 0.033) 和甲状腺功能中观察到显著的改善.
- 实验组和对照组的不良事件发生率相似 (p = 0.628).
结论:
- 在标准HFrEF治疗中添加L-T4,在6个月内改善了HFrEFSCH患者的活性耐受性,NYHA类和甲状腺功能.
- 这些发现表明,L-T4可能是这种患者群体标准治疗的有益补充.
- 需要进一步的双盲,安慰剂对照试验来证实这些结果.
关键词:
6MWT 6MWT 6MWT 6MWT 6MWT 6MWT 6MWT 6MWT尼哈尼哈 (NYHAHA) 是一个名字.慢性心力衰竭是一种慢性心力衰竭.莱沃甲氧氨酸 (Levothyroxine) 是一种抗氧化剂.亚临床的甲状腺功能低下症更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:20Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K